The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care Cancer palliative care

BMC Palliative Care

Volumn 14, Issue 1, 2015, Pages

  Chou, Wen Chi ^a   Kao, Chen Yi ^a   Wang, Po Nan ^a   Chang, Hung ^a   Wang, Hung Ming ^a   Chang, Pei Hung ^b   Yeh, Kun Yun ^b   Hung, Yu Shin ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Charlson comorbidity index; Glasgow prognostic score; Hematologic malignancy; Palliative care; Palliative prognostic index; Prognostication

Indexed keywords

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; FEMALE; GLASGOW PROGNOSTIC SCORE; HEMATOLOGIC MALIGNANCY; HUMAN; INSTRUMENT VALIDATION; LIFE EXPECTANCY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE MYELOMA; PALLIATIVE PROGNOSTIC INDEX; PROGNOSTIC ASSESSMENT; SURVIVAL TIME; TAIWAN; TERMINALLY ILL PATIENT; AGE; COMORBIDITY; EPIDEMIOLOGY; HEALTH STATUS INDICATOR; HEMATOLOGIC NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SOCIOECONOMICS; TIME FACTOR;

ADULT; AGE FACTORS; AGED; COMORBIDITY; FEMALE; HEALTH STATUS INDICATORS; HEMATOLOGIC NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIOECONOMIC FACTORS; TAIWAN; TERMINALLY ILL; TIME FACTORS;

EID: 84976420240     PISSN: None     EISSN: 1472684X     Source Type: Journal    
DOI: 10.1186/s12904-015-0011-5     Document Type: Article

References (26)

1. Hung YS, Wu JH, Chang H, Wang PN, Kao CY, Wang HM, et al. Characteristics of patients with hematologic malignancies who received palliative care consultation services in a medical center. Am J Hosp Palliat Care. 2013;30:773-80.
2. Health Registry Annual Report 2009, Republic of China. Republic of China: Bureau of Health Promotion, Department of Health, executive Yuan, Republic of China. 2011.
3. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer. 1999;7:128-33.
4. Stone CA, Tiernan E, Dooley BA. Prospective validation of the palliative prognostic index in patients with cancer. J Pain Symptom Manage. 2008;35:617-22.
5. Maltoni M, Scarpi E, Pittureri C, Martini F, Montanari L, Amaducci E, et al. Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist. 2012;17:446-54.
6. Cheng WH, Kao CY, Hung YS, Su PJ, Hsieh CH, Chen JS, et al. Validation of a palliative prognostic index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan. Asian Pacific J Cancer Prev. 2012;13:2861-6.
7. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998;53:M372-8.
8. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-7.
9. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961-8.
10. Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165:489-96.
11. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009;27:148-53.
12. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012;91:1383-91.
13. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-40.
14. Bureau of National Health Insurance, Taiwan, Republic of China. Symptom record form in patients with terminal illness disease for hospice consultation care nurse specialist. Available from http://www.nhi.gov.tw/information/bbs-detail.aspx?bulletin-ID1404&menu9&menu-id545. Accessed May 08, 2015.
15. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative Performance Scale (PPS): a new tool. J Palliat Care. 1996;12:5-11.
16. Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, Banerjee S, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer. 2010;46:3175-83.
17. Kao CY, Hung YS, Wang HM, Chen JS, Chin TL, Lu CY, et al. Combination of initial palliative prognostic index and score change provides a better prognostic value for terminally ill cancer patients: a six year observational cohort study. J Pain Symptom Manage. 2014;14:S0885-3924.
18. Hung CY, Wang HM, Kao CY, Lin YC, Chen JS, Hung YS, et al. Magnitude of score change for the palliative prognostic index for survival prediction in patients with poor prognostic terminal cancer. Support Care Cancer. 2014;22(10):2725-31.
19. Viganò A, Bruera E, Suarez-Almazor ME. Terminal cancer syndrome: myth or reality ? J Palliat Care. 1999;15:32-9.
20. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104-11.
21. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223-6.
22. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028-30.
23. Maillet M, Dréanic J, Dhooge M, Mir O, Brezault C, Goldwasser F, et al. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab. Anticancer Drugs. 2014;25(10):1215-9.
24. Dréanic J, Maillet M, Dhooge M, Mir O, Brezault C, Goldwasser F, et al. Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies. Med Oncol. 2013;30(3):656.
25. Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium-a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013;31:2810-8.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-83.